Article Text

Download PDFPDF
Clinical efficacy with dabrafenib and trametinib in a T599_V600insT poorly differentiated metastatic thyroid carcinoma
  1. Chung-Shien Lee1,2,
  2. Emily Miao3,
  3. Kasturi Das4 and
  4. Nagashree Seetharamu1,5
  1. 1Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Lake Success, New York, USA
  2. 2Clinical Health Professions, St John's University, Queens, New York, USA
  3. 3Pharmacy Department, North Shore University Hospital, Manhasset, New York, USA
  4. 4Division of Cytopathology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Greenvale, New York, USA
  5. 5Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA
  1. Correspondence to Dr Chung-Shien Lee; leec3{at}stjohns.edu

Abstract

BRAF (v-raf murine sarcoma viral oncogene homolog B1) and MEK (mitogen-activated protein kinase kinase) inhibitors have been shown to improve clinical outcomes in tumours presenting with mutations in the BRAF gene. The most common form of BRAF mutation is V600E/K and has been shown to occur in thyroid cancers. Treatment data for patients harbouring less frequent BRAF mutations are limited. In vitro studies have shown that mutations in codons 599–601 increase kinase activity similar to that in V600E mutations, which suggests that BRAF and MEK inhibitors could be an effective treatment option. Here, we report a case of a patient with thyroid carcinoma harbouring a rare amino acid insertion in codon 599 of the BRAF gene (T599_V600insT) treated with a BRAF and MEK inhibitor.

  • cancer intervention
  • oncology
  • tyrosine kinase inhibitor

Statistics from Altmetric.com

Footnotes

  • Contributors All authors have made an individual contribution to the writing of the article. C-SL is the lead author who drafted the case report and was involved in discussing, reporting and interpretation of the case report. EM is a coauthor and was involved in the development of the case report and was involved in discussing, reporting and interpretation of the case report. KD is a coauthor and was involved in the development of the case report and was involved in discussing, reporting and interpretation of the case report. NS is a coauthor and was involved in the development of the case report and was involved in discussing, reporting and interpretation of the case report.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests NS has participated on advisory boards for Amgen, Genentech, Takeda and AstraZeneca and is a consultant for Boehringer Ingelheim. C-SL has participated on advisory boards for G1 Therapeutics.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.